Find Clinical Trials
A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy disease
Servier Protocol Code:
CL2-78989-010
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2012-005772-34
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Muscular disease
- GEVOKIZUMAB
- S078989
Other study id numbers
Other identification numbers the study may be known by.
- CL2-78989-010